一种新型全人源重组FSH(促卵泡素ε):两项安慰剂和对照药对照的I期随机药代动力学和药效学试验
两项I期随机单盲试验在健康垂体抑制女性中比较新型全人源重组FSH促卵泡素ε与CHO来源及尿源FSH。促卵泡素ε单次和多次给药的药代动力学与对照药相当,药效学上促卵泡素ε在卵泡生长和抑制素B方面活性最强,安全耐受性良好。
要点
- 促卵泡素ε单次和多次给药的Cmax和AUC0-last随剂量线性增加,药代动力学与对照药相当。
- 促卵泡素ε对卵泡生长和抑制素B呈剂量反应效应,药效学活性强于对照药。
- 所有测试剂量安全耐受,未观察到抗药抗体,不良事件平均数量随剂量增加。
核心结论
- 促卵泡素ε具有全人源糖基化,单次和多次给药的药代动力学与CHO来源重组FSH及尿源FSH相当,而药效学特性因产品而异,促卵泡素ε在药效学参数上活性最强。
- 作者认为这些早期开发研究结果表明促卵泡素ε具有可比的药代动力学特性,并在卵泡生长和血清抑制素B方面诱导比对照药更强的药效学效应。
研究设计与样本
- 两项随机、安慰剂和对照药对照、单盲I期研究,纳入18至40岁健康垂体抑制女性志愿者。
- 单次给药剂量递增研究纳入19名女性(2011年4月至2011年9月),每名受试者接受三个递增剂量或安慰剂/对照药,给药间有14天洗脱期。
- 多次给药研究纳入57名女性(2011年10月至2012年4月),分五个队列,三个剂量水平对比安慰剂和两种对照药。
- 单次给药研究中12名受试者接受促卵泡素ε(25、75、150和300 IU)四个可能递增剂量中的三个,7名受试者每个治疗期按随机顺序接受两种对照药各一剂(150 IU Bravelle和150 IU Gonal-f)及安慰剂。
- 多次给药研究中30名受试者接受促卵泡素ε(75 IU或150 IU每日一次,或150 IU隔日一次,各10名),27名受试者接受150 IU Gonal-f、150 IU Bravelle或安慰剂7天(分别为11/10/6名)。
主要发现
- 促卵泡素ε单次和多次给药的Cmax和AUC0-last随剂量水平增加呈线性增加。
- 促卵泡素ε对卵泡生长呈剂量反应效应,生物标志物抑制素B以及卵泡平均数量和大小均显示该效应。
- 每日75 IU促卵泡素ε及隔日150 IU促卵泡素ε的卵泡生长与每日150 IU Gonal-f相当,而每日150 IU Bravelle仅观察到弱卵泡刺激。
- 多次给予150 IU促卵泡素ε诱导的卵泡生长远高于相同剂量的Gonal-f。
- 所有测试的单次和多次促卵泡素ε剂量安全且耐受良好,促卵泡素ε与对照药在安全性方面总体无相关差异,不良事件平均数量随剂量水平增加,未观察到促卵泡素ε抗药抗体。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究为单盲设计。
- 血清中评估的激素水平或其他参数通常不被认为受偏倚影响,而研究者直接进行的其他评估如经阴道超声评估可能受个人偏倚影响。
- 未进行前瞻性统计功效计算,这在健康志愿者首次人体和早期I期研究中是常见做法。
- 作者认为结果 warrant 进一步研究这种新型全人源重组FSH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the differences and similarities of pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the novel recombinant human FSH follitropin epsilon expressed in the human cell line GlycoExpress compared with a Chinese hamster ovary (CHO) derived compound and a urinary derived product? SUMMARY ANSWER: Overall follitropin epsilon, with a fully human glycosylation, shows a comparable PK profile at single-dose as well as multiple-dose administration compared to recombinant CHO-derived FSH as well as urinary derived FSH, whereas the PD properties differ from product to product with follitropin epsilon being most active in PD parameters. WHAT IS KNOWN ALREADY: Recombinant FSH produced in CHO and FSH obtained from the urine of postmenopausal women show comparable PK and PD properties. However, more recently a comparative study of a recombinant FSH produced in the human cell line PerC6 and a CHO-derived FSH preparation revealed differences in PK and PD properties of the molecule. STUDY DESIGN, SIZE, DURATION: Both studies were randomized, placebo- and comparator-controlled, single-blind phase I studies in healthy pituitary-suppressed female volunteers aged 18 and 40 years. The single-dose, dose escalation study included 19 women (April 2011 to September 2011) with three ascending dose levels per subject or placebo/comparators with a 14-day washout phase between dosings. The multiple-dose study included 57 women (October 2011 to April 2012) in five cohorts with three dose levels versus placebo and two comparators. Randomization to the respective treatment was performed after successful downregulation of the pituitary gland prior to Investigational Medicinal Product dosing. PARTICIPANTS/MATERIALS, SETTING, METHODS: In the single-dose study, 12 subjects received follitropin epsilon (25, 75, 150 and 300 IU) in three of four possible ascending doses and seven subjects received one dose of two comparators (150 IU Bravelle and 150 IU Gonal-f) and placebo in random order in each treatment period. In the multiple-dose study, 30 subjects received follitropin epsilon (75 IU or 150 IU once daily [QD], or 150 IU every other day [QAD], 10 subjects each) and 27 subjects received 150 IU Gonal-f, 150 IU Bravelle, or placebo for 7 days (11/10/6 subjects). Blood samples for measuring PK as well as PD parameters were collected systematically before, during and after dosing. Adverse events (AEs) and other relevant safety parameters were recorded. Data were summarized using descriptive statistics. MAIN RESULTS AND THE ROLE OF CHANCE: The single- and multiple-dose PK parameters maximum concentration (Cmax) and area under the concentration-time curve (AUC0-last) increased in a linear fashion with increasing dose levels of follitropin epsilon. Follitropin epsilon showed PK characteristics comparable to the comparators indicating that well established treatment schemes could be applied. There was a dose-response effect of single and multiple doses of follitropin epsilon on follicular growth, which was shown for the biomarker inhibin B as well as for the mean number and size of follicles. Multiple doses of 75 IU follitropin epsilon given daily, as well as 150 IU follitropin epsilon every second day, showed a follicle growth comparable with 150 IU Gonal-f given daily, while in case of daily administration of 150 IU Bravelle only weak follicle stimulation was observed. Multiple doses of 150 IU follitropin epsilon induced a much higher follicle growth compared to the same dose of Gonal-f. All single and multiple follitropin epsilon doses tested were safe and well tolerated, and overall there were no relevant differences between follitropin epsilon and the comparators in terms of safety. The average number of AEs increased with increasing dose levels. No clinically relevant abnormalities were reported for any of the other safety parameters assessed. No follitropin epsilon anti-drug antibodies were observed. LIMITATIONS, REASONS FOR CAUTION: The studies were conducted as a single-blind design. Hormone levels or other parameters assessed in serum are generally not considered as being subject to bias. Other assessments directly performed by the investigators, such as transvaginal ultrasound assessments, may have been subject to personal bias. No prospective calculations of statistical power had been made, as is common practice for first in human and early phase I studies in healthy volunteers. WIDER IMPLICATIONS OF THE FINDINGS: These early development studies showed that follitropin epsilon exhibits comparable PK characteristics, as well as inducing stronger PD effects in terms of follicle growth and serum inhibin B, than the comparators. Follitropin epsilon induced a dose-dependent increase in follicular growth. The results warrant further studies with this new fully human recombinant FSH. STUDY FUNDING/COMPETING INTEREST(S): The studies were sponsored by GLYCOTOPE GmbH, Berlin, Germany. K.A-E. is an employee of QPS-Netherlands, B.V., which received funding for the studies from Glycotope GmbH; I.D. and C.K. are employees of Dinox B.V., which received funding for the studies from Glycotope GmbH; L.S. and S.G. are employees and shareholders of Glycotope GmbH; B.D. and K.E. are employees of Glycotope GmbH. TRIAL REGISTRATION NUMBER: www.clinicaltrials.gov: NCT01354886 (single-dose); NCT01477073 (multiple-dose). TRIAL REGISTRATION DATE: The single-dose trial was registered on 11 May 2011 while the multiple-dose trial was registered on 09 November 2011. DATE OF FIRST SUBJECT'S ENROLMENT: First subject was enroled in the single-dose trial in 27 April 2011 and in the multiple-dose trial in 02 October 2011.
引用
- Abd-Elaziz K, Duijkers I, Stöckl L, et al. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials. Hum Reprod. 2017. PMID: 28591833. doi:10.1093/humrep/dex220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。